Fundraising Fox

FGH Biotech

Houston, US · Founded 2011 · Delaware corporation

FGH BioTech develops small molecule drugs that regulate SREBP transcription factors and related pathways, targeting the prevention and treatment of metabolic diseases and cancer. The company's work is based on decades of research in fat and energy metabolism.

Founders & leadership

LA
Lufti Abu-ElheigaExecutive
JW
Joe WakilExecutive

Board

AK
Adam KuspaBoard director

Reported raises · per SEC filings

Form D private placements

$2.1M disclosed across 1 of 2 rounds · 2015–2017

$2.1MraisedMay 2018 · 18 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Lufti Abu-ElheigaExecutive Officer
  • Joe WakilExecutive Officer, Director
  • Salih J WakilExecutive Officer, Director
  • Adam KuspaDirector
Offering amount
$4M
Amount sold
$2.1M
Minimum investment
$12.5K
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$2.5MofferedNov 2015 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Adam KuspaDirector
  • Lufti Abu-ElheigaExecutive Officer
  • Joe WakilExecutive Officer, Director
  • Salih J WakilExecutive Officer, Director
Offering amount
$2.5M
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does FGH Biotech do?
FGH BioTech develops small molecule drugs that regulate SREBP transcription factors and related pathways, targeting the prevention and treatment of metabolic diseases and cancer. The company's work is based on decades of research in fat and energy metabolism.
How much funding has FGH Biotech raised?
FGH Biotech has disclosed $2.1M raised across 1 of its 2 known rounds.
Where is FGH Biotech headquartered?
FGH Biotech is headquartered in Houston, US.